IDH1 & IDH2 Mutation Analysis

Last Modified: 3/3/2020 1:51:47 PM


Specimen Requirements:

FFPE tissue: Paraffin block
Collection Instructions: Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Transport & Storage: Temperature/Stability: Refrigerate, and use cold pack for transport, cold pack should not be in direct contact with specimen
Reference Range: Refer to Interpretive Results
Methodology: Molecular
Clinical Significance: IDH1 or IDH2 mutations are detected in approximately 15-20% of acute myeloid leukemia (AML) and >70% grade II or III brain gliomas. Patients with AML and mutations are likely to have aggressive disease, while mutations in gliomas are associated with better prognosis. Long-term survival after aggressive tumor resection has been reported for patients with IDH1-positive astrocytomas
Custom Panel: No

PRODUCTION SCHEDULE

Turn Around Time: 7 to 8 days
Sites Performed: NeoGenomics
PHL Test Code: PS
EPIC Test Code: N/A
Send Out Test Code: Soft Path - IDH1 & IDH2
Alternate Test Names: IDH1 Mutation Analysis; IDH2 Mutation Analysis
Included Tests: IDH1 Mutation Analysis; IDH2 Mutation Analysis
CPT Coding: 81120, 81121

Go back to the top of the page.